Charles Schwab’s Alpine Immune Sciences Inc ALPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-339,142
| Closed | -$13.4M | – | 3714 |
|
|
2024
Q1 | $13.4M | Buy |
339,142
+41,690
| +14% | +$1.23M | ﹤0.01% | 1831 |
|
|
2023
Q4 | $5.67M | Buy |
297,452
+63,196
| +27% | +$878K | ﹤0.01% | 2257 |
|
|
2023
Q3 | $2.68M | Buy |
234,256
+147,976
| +172% | +$1.82M | ﹤0.01% | 2512 |
|
|
2023
Q2 | $887K | Buy |
86,280
+19,014
| +28% | +$171K | ﹤0.01% | 2813 |
|
|
2023
Q1 | $519K | Buy |
67,266
+2,770
| +4% | +$22.1K | ﹤0.01% | 2935 |
|
|
2022
Q4 | $474K | Buy |
64,496
+24,673
| +62% | +$158K | ﹤0.01% | 3017 |
|
|
2022
Q3 | $287K | Hold |
39,823
| – | – | ﹤0.01% | 3117 |
|
|
2022
Q2 | $339K | Buy |
39,823
+7,406
| +23% | +$63.8K | ﹤0.01% | 3174 |
|
|
2022
Q1 | $291K | Buy |
32,417
+2,294
| +8% | +$19.8K | ﹤0.01% | 3222 |
|
|
2021
Q4 | $418K | Buy |
30,123
+5,500
| +22% | +$68.1K | ﹤0.01% | 3204 |
|
|
2021
Q3 | $263K | Sell |
24,623
-4,137
| -14% | -$38.1K | ﹤0.01% | 3290 |
|
|
2021
Q2 | $259K | Buy |
+28,760
| New | +$313K | ﹤0.01% | 3255 |
|
Charles Schwab's ALPN Position: Q2 2024 in Review
Charles Schwab sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 339,142 shares — an estimated $13.4M sold.
Charles Schwab first reported a position in ALPN in Q2 2021 and held it in 12 quarters. The position peaked at $13.4M in Q1 2024. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.
- Charles Schwab reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
- Charles Schwab sold 339,142 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $13.4M.
- Charles Schwab first reported a position in Alpine Immune Sciences Inc in Q2 2021 and held it in 12 quarters.
- Charles Schwab's Alpine Immune Sciences Inc position peaked at $13.4M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.
Based on Charles Schwab's 13F filing for Q2 2024, filed 12 Aug 2024.